4.78

0.63% 0.03

After Hours: 4.71 -0.07 -1.46%

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $4.78, with a volume of 997.14K. It is up +0.63% in the last 24 hours and up +25.79% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Previous Close:

$4.75

Open:

$4.81

24h Volume:

997.14K

Relative Volume:

0.57

Market Cap:

$667.59M

Revenue:

$7.83M

Net Income/Loss:

$-64.92M

P/E Ratio:

-9.024

EPS:

-0.5297

Net Cash Flow:

$-47.22M

1W Performance:

+6.94%

1M Performance:

+25.79%

6M Performance:

+110.57%

1Y Performance:

+273.44%

1-Day Range:

$4.695

$4.875

1-Week Range:

$4.215

$4.88

52-Week Range:

$1.16

$4.89

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2026-05-14

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	4.78	663.40M	7.83M	-64.92M	-47.22M	-0.5297
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Initiated	Oppenheimer	Outperform
Jul-10-25	Resumed	Piper Sandler	Overweight
May-28-25	Initiated	Wedbush	Outperform
Mar-18-25	Resumed	Cantor Fitzgerald	Overweight
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

06:59 AM

Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation - MSN

06:59 AM

May 05, 2026

MSN Money - MSN

May 05, 2026

Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld - Stock Titan

May 05, 2026

Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo

May 05, 2026

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

May 05, 2026

Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 - Moomoo

May 05, 2026

Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline - MyChesCo

May 05, 2026

May 04, 2026

Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView

May 04, 2026

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - Yahoo Finance

May 04, 2026

May 03, 2026

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

May 03, 2026

Apr 28, 2026